News | October 22, 2014

Cytori Technology Selected for NHLBI Trial in LVAD Patients

Thirty-four patients will be selected to assess safety, feasibility of regenerative cell therapy

October 22, 2014 — The Cardiovascular Cell Therapy Research Network (CCTRN) has selected Cytori Therapeutics Inc. to supply adipose-derived regenerative cells (ADRC) for a clinical trial aimed at evaluating the safety and feasibility of treating patients with left ventricular assist devices (LVADs). The CCTRN is supported by grants from the National Heart, Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH). This trial, named CELLVAD-ADRC, will explore outcomes following administration of a regenerative cell preparation from adipose tissue into the patient’s heart muscle 60 to 90 days after placement of an LVAD.

CELLVAD-ADRC is a prospective, phase I, double-blind randomized trial that will enroll 34 patients with end-stage ischemic heart disease who have received an LVAD in the preceding 60 to 90 days. Following an open-label phase where the initial 10 patients will all receive cell therapy subject to a safety committee review, 24 patients will be randomized 1:1 to receive either ADRCs or a placebo. The trial will assess safety and feasibility endpoints including adverse events, cardiac function, exercise tolerance, myocardial viability and perfusion and quality of life over a one-year follow-up period. The trial is funded by the NHLBI through CCTRN, which will oversee trial design, implementation and enrollment across its network of seven U.S. trial sites, which lead the field of cardiovascular cell therapy.

Cytori Cell Therapy is a mixed population of autologous adipose-derived regenerative cells (ADRCs) extracted using Cytori’s proprietary Celution System, creating new treatment opportunities for currently unmet medical needs. Adipose tissue is the richest source of stem and regenerative cells in the body. LVADs are mechanical devices used in hearts too weak to pump blood throughout the body. They are commonly implanted in patients waiting for a transplant or who do not qualify for a transplant but need additional pumping support.

According to the American Heart Association, there are approximately 5.1 million Americans currently living with heart failure. For patients with a more advanced condition of heart failure, ventricular assist devices are sometimes an option. In 2010, more than 1,400 LVAD devices were implanted into patients in the U.S. alone.

For more information: www.nhlbi.nih.gov, www.cytori.com

Related Content

Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Left Atrial Pressure Monitor from Vectorious Medical Technologies Offers New Hope for Heart Failure Patients

On of the top stories in July was the introduction of a left atrial pressure monitor from Vectorious Medical Technologies to prevent heart failure patient hospitalizations or readmissions. Read the article"Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients."

Feature | August 01, 2017 | Dave Fornell
Aug.
Wearable monitors create patient generated health data, PGHD, that can help prevent acute care episodes in heart failure.

Wearable monitoring devices may offer a new tool to help prevent acute care episodes in heart failure.

Feature | Heart Failure| July 25, 2017 | Lola Koktysh
Despite their best efforts, many patients tend to develop heart failure after an acute event (e.g., a heart attack or
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT)| July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Hospital Readmissions Analysis Across All Ages, Insurance Types Identifies High-Risk Groups
News | Business| July 20, 2017
July 20, 2017 — Clinician-researchers at Beth Israel Deaconess Medical Center (BIDMC) recently published a first-of-i
Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients
News | Heart Failure| July 14, 2017
A review appearing in the July 18 issue of the Journal of the American College of Cardiology (JACC) discusses current...
Overlay Init